Evidence map›Paper›PMID 38745654›Full record

ArticleFrontiers in immunology2024

H-intensity scale score to estimate CSF GluN1 antibody titers with one-time immunostaining using a commercial assay.

Masaki Iizuka, Naomi Nagata, Naomi Kanazawa, Tomomi Iwami, Makoto Nagashima, Masaaki Nakamura, Juntaro Kaneko, Eiji Kitamura, Kazutoshi Nishiyama, Noritaka Mamorita and 1 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Masaki IizukaDepartment of Neurology, Kitasato University School of Medicine, Sagamihara, Japan.
Naomi NagataDepartment of Neurology, Kitasato University School of Medicine, Sagamihara, Japan.
Naomi KanazawaDepartment of Neurology, Kitasato University School of Medicine, Sagamihara, Japan.
Tomomi IwamiDepartment of Neurology, Kitasato University School of Medicine, Sagamihara, Japan.
Makoto NagashimaDepartment of Neurology, Kitasato University School of Medicine, Sagamihara, Japan.
Masaaki NakamuraDepartment of Neurology, Kitasato University School of Medicine, Sagamihara, Japan.
Juntaro KanekoDepartment of Neurology, Kitasato University School of Medicine, Sagamihara, Japan.
Eiji KitamuraDepartment of Neurology, Kitasato University School of Medicine, Sagamihara, Japan.
Kazutoshi NishiyamaDepartment of Neurology, Kitasato University School of Medicine, Sagamihara, Japan.
Noritaka MamoritaDepartment of Medical Informatics, Kitasato University School of Allied Health Sciences, Sagamihara, Japan.
Takahiro IizukaDepartment of Neurology, Kitasato University School of Medicine, Sagamihara, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Anti-NMDA receptor encephalitis is an autoimmune disorder caused by autoantibodies (abs) against the conformational epitope on GluN1 subunits. GluN1-abs have been determined with cell-based assay (CBA) co-expressing GluN1/GluN2 subunits. However, commercial fixed CBA expressing only GluN1 subunit has increasingly been used in clinical practice. The ab titers can be determined with serial dilutions, but its clinical significance remains unclear. We aimed to develop an H-intensity scale (HIS) score to estimate GluN1-ab titers in cerebrospinal fluid (CSF) with one-time immunostaining using both commercial CBA and immunohistochemistry and report its usefulness. "H" is the initial of a patient with high CSF GluN1-ab titers (1:2,048). Methods: We first determined the reliability of CBA in 370 patients with suspected autoimmune encephalitis by comparing the results between commercial CBA and established assay in Dalmau's Lab. Then, we made positive control panels using the patient H's CSF diluted in a fourfold serial dilution method (1:2, 1:8, 1:32, 1:128, 1:512, and 1:2,048). Based on the panels, we scored the intensity of ab reactivity of 79 GluN1-ab-positive patients' CSF (diluted at 1:2) on a scale from 0 to 6 (with ≥1 considered positive). To assess inter-assay reliability, we performed immunostaining twice in 21 patients' CSF. We investigated an association between the score of CSF obtained at diagnosis and the clinical/paraclinical features. Results: The sensitivity and specificity of CBA were 93.7% (95% CI: 86.0-97.3) and 98.6% (95% CI: 96.5-99.5), respectively. Linear regression analysis showed a good agreement between the scores of the first and second assays. Patients with a typical spectrum, need for mechanical ventilation support, autonomic symptoms/central hypoventilation, dyskinesias, speech dysfunction, decreased level of consciousness, preceding headache, ovarian teratoma, and CSF leukocyte count >20 cells/µL had a higher median HIS score than those without, but HIS score was not associated with sex, age at onset, or seizure. HIS score at diagnosis had a significant effect on 1-year functional status. Discussion: The severity of disease and four of the six core symptoms were associated with higher GluN1-ab titers in CSF at diagnosis, which may play a role in poor 1-year functional status. An incomplete phenotype can be attributed to low CSF GluN1-ab titers.

Indexed as

Anti-N-Methyl-D-Aspartate Receptor EncephalitisImmunohistochemistryAdolescentAdultAgedAged, 80 and overAutoantibodiesBiomarkersChildChild, PreschoolFemaleHumansMaleMiddle AgedNerve Tissue ProteinsReceptors, N-Methyl-D-AspartateAutoantibodiesBiomarkersNerve Tissue ProteinsReceptors, N-Methyl-D-Aspartateautoantibodiescell-based assayimmunohistochemistryNMDA receptor encephalitistissue-based assay

Identifiers

PMID38745654
PMCPMC11091310

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.